Zenith Technologies sees 400% China growth in latest Asia success
Company plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.
Zenith Technologies, a world leader in delivering manufacturing software solutions to the life sciences industry, has reported 400% growth in its Chinese operations in the last 3 years.
The company now has a presence working on sites across five Chinese cities – Shanghai, Suzhou, Xi’an, Hangzhou & Guangzhou - and employs a growing team to work across its client base supporting pharma and biotech companies with the implementation of technologies to improve manufacturing efficiencies such as automation, IT, manufacturing execution systems (MES) and digital and data analysis.
With the Chinese life sciences market currently set as the world’s second largest national market, and with an expected value of $220 billion by 2022, Zenith plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.
Liang Zhou, General Manager of Greater China said: “The Chinese market has been leading the way in revolutionary cell therapy innovations, which are changing the face of medicine delivery. There is growing interest in the adoption of automating processes in this area as companies build a new generation of facilities in line with stringent international standards with a view to supplying across the world.
“We are well placed to support clients here who would like to adopt these solutions and have already played an integral role in the development of technologies to oversee these key cell therapy innovations.”
Zenith’s success in China represents the company’s latest endeavour in the Asian market having first set up a presence on the continent in 2002 with the opening of its regional headquarters in Singapore.
In 2008 the company set up an office in India, which now hosts more than 100 employees and serves as a global support hub to deliver software projects anywhere in the world, featuring a remote engineering centre and 24/7 IT support desk service.
Across the continent, Zenith now has a total workforce of more than 200 professionals and is actively looking to new Asian markets to expand its footprint to support the burgeoning number of life science hubs.
Bryan McSwiney, Asia Director said: “After more than 15 years in the Asian market, a quarter of our global operations are now based here and the latest growth figures from China demonstrate that we go from strength to strength.
“We now have an established presence in five Chinese cities – a significant footprint within a relatively short space of time – as well as a thriving support hub in India and a widely recognised HQ in Singapore.
“With a solid foundation now firmly established in the Asian market, we look forward to building on our successes and working closely with local and multinational companies on the continent who can benefit from the diverse range of technologies we can introduce into manufacturing facilities.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance